1609980-39-3

Basic information

• Product Name: 2-[2-(4-chlorophenoxy)ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• Synonyms: 2-[2-(4-chlorophenoxy)ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• CAS NO: 1609980-39-3
• Molecular Weight: 318.763
• Mol File: 1609980-39-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[2-(4-chlorophenoxy)ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(4-chlorophenoxy)ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(1609980-39-3)
• EPA Substance Registry System: 2-[2-(4-chlorophenoxy)ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(1609980-39-3)

Safety Data

• Hazardous Substances Data: 1609980-39-3(Hazardous Substances Data)

Usage

Chemical Class

The compound belongs to the class of triazolopyrimidine derivatives.

Molecular Weight

The molecular weight of the compound is 307.75 g/mol.

Pharmaceutical Applications

The compound has potential pharmaceutical applications and is a key ingredient in the development of new drugs and medications.

Safety Precautions

It is important to handle this chemical with care and follow proper safety protocols due to its potential health hazards and environmental impacts.

Storage and Handling

The compound may require special storage and handling procedures to ensure safety and effectiveness.

Upstream product

• 106-48-9 4-chloro-phenol 
• 1892-43-9 2-(4-chlorophenoxy)ethanol 
• 51646-19-6 5,7-dimethyl-2-methylthio-1,2,4-triazolo<1,5-a>pyrimidine 
• 123-54-6 acetylacetone 

Relevant articles and documents

Discovery and characterization of nonpeptidyl agonists of the tissue-protective erythropoietin receptors

Erythropoietin (EPO) and its receptor are expressed in a wide variety of tissues, including the central nervous system. Local expression of both EPO and its receptor is upregulated upon injury or stress and plays a role in tissue homeostasis and cytoprotection. High-dose systemic administration or local injection of recombinant human EPO has demonstrated encouraging results in several models of tissue protection and organ injury, while poor tissue availability of the protein limits its efficacy. Here, we describe the discovery and characterization of the nonpeptidyl compound STS-E412 (2-[2-(4-chlorophenoxy) ethoxy]-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine), which selectively activates the tissue-protective EPO receptor, comprising an EPO receptor subunit (EPOR) and the common β-chain (CD131). STS-E412 triggered EPO receptor phosphorylation in human neuronal cells. STS-E412 also increased phosphorylation of EPOR, CD131, and the EPO-associated signaling molecules JAK2 and AKT in HEK293 transfectants expressing EPOR and CD131. At low nanomolar concentrations, STS-E412 provided EPO-like cytoprotective effects in primary neuronal cells and renal proximal tubular epithelial cells. The receptor selectivity of STS-E412 was confirmed by a lack of phosphorylation of the EPOR/EPOR homodimer, lack of activity in off-target selectivity screening, and lack of functional effects in erythroleukemia cell line TF-1 and CD34+ progenitor cells. Permeability through artificial membranes and Caco-2 cell monolayers in vitro and penetrance across the blood-brain barrier in vivo suggest potential for central nervous system availability of the compound. To our knowledge, STS-E412 is the first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor. Further evaluation of the potential of STS-E412 in central nervous system diseases and organ protection is warranted.